Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thierry Charron is active.

Publication


Featured researches published by Thierry Charron.


Circulation | 2008

Microvascular Obstruction and the No-Reflow Phenomenon After Percutaneous Coronary Intervention

Ronen Jaffe; Thierry Charron; Geoffrey Puley; Alexander Dick; Bradley H. Strauss

C ase presentation A: A 50-year-old diabetic man presented to the hospital after 8 hours of continuous chest pain. Because of acute myocardial infarction of the anterior wall, he underwent direct stenting to an occlusion in the left anterior descending coronary artery. Despite revascularization, suboptimal coronary flow was achieved, and he subsequently developed heart failure. Case presentation B: A 77-year-old man underwent elective stenting of a significant stenosis in a degenerated saphenous vein coronary bypass graft. After the procedure, coronary flow in the graft was severely reduced, and he sustained a myocardial infarction in the subtended myocardial territory. The concept of “no reflow” refers to a state of myocardial tissue hypoperfusion in the presence of a patent epicardial coronary artery. The underlying cause of no reflow is microvascular obstruction, which may be produced by various mechanisms. No reflow can be classified according to the duration of the preceding myocardial ischemia (Figure 1). “Reperfusion no reflow” occurs after primary percutaneous coronary intervention (PCI) for reperfusion of an infarct artery in the setting of acute myocardial infarction (AMI) and may be asymptomatic or may present clinically with continued chest pain and ST-segment elevation. Reperfusion no reflow is preceded by ischemic cell injury, is confined to the irreversibly damaged necrotic zone, and may be exacerbated at the time of reperfusion. Reperfusion no reflow is an independent predictor of adverse clinical outcome after AMI regardless of infarct size and is associated with heart failure and increased mortality.1 Figure 1. Schematic illustrating the effect of duration of preceding myocardial ischemia on mechanism of no reflow (NR). “Interventional no reflow” follows noninfarct PCI and affects myocardium that was not subjected to prolonged ischemia before the procedure. Clinically recognized interventional no reflow that complicates PCI is typically sudden in onset, presenting as acute ischemia with chest …


Catheterization and Cardiovascular Interventions | 2013

Porcine model of intracoronary pulverization of stent struts by rotablation atherectomy

Thuy Tran Quang; Raja Hatem; Guy Rousseau; Bruno Dube; Caroline Samson; Erick Schampaert; Thierry Charron

To evaluate the feasibility and safety of rotablation atherectomy in a suboptimally expanded stent.


Thrombosis Research | 2010

Effects of distal embolization on the timing of platelet and inflammatory cell activation in interventional coronary no-reflow

Thierry Charron; Ronen Jaffe; Amit Segev; K.W. Annie Bang; Beiping Qiang; John D. Sparkes; Jagdish Butany; Alexander Dick; John Freedman; Bradley H. Strauss


Archive | 2013

METHOD AND DEVICE FOR INFUSION OF PHARMACOLOGIC AGENTS AND THROMBUS ASPIRATION IN ARTERY

Thierry Charron; Domenic Santoianni; Marwan Abboud; Guy Rousseau; Aimé-robert Leblanc


Archive | 2007

Iron-overload Cardiomyopathy Associated with Iron-overload Conditions: Incidence, Pathophysiology, and Treatment

Y. Oudit; G Ordon Moe; Beth L. Abramson; Luigi Casella; Thierry Charron; Asim N. Cheema; Robert J. Chisholm; Chi-Ming Chow; Paul Dorian; David Fitchett; Michael R. Freeman; Shaun Goodman; Anthony F. Graham; Robert J. Howard; Stuart Hutchison; Victoria Korley; Michael Kutryk; Anatoly Langer; Howard Leong-Poi; Iqwal Mangat; Gordon W. Moe; Juan C. Monge; Thomas G. Parker; Arnold Pinter; Trevor I. Robinson; Duncan J. Stewart; Bradley H. Strauss


World Journal of Cardiovascular Diseases | 2013

Dual effect of pre-ischemic administration of TNF-alpha on myocardial infarct size

Thuy Tran Quang; Raja Hatem; Guy Rousseau; Audrey-Anne Gosselin; Erick Schampaert; Thierry Charron


Archive | 2013

Device for infusion of pharmacologic agents and thrombus aspiration in artery

Thierry Charron; Domenic Santoianni; Marwan Abboud; Guy Rousseau; Aimé-robert Leblanc


Circulation | 2010

Abstract 10176: Serotonin Blockade with Ketanserin Attenuates ST-segment Depression and Myocardial Perfusion Defects Secondary to Collagen-induced Platelet Activation in Swine

Sherif Shousha; Chantal Pharand; Marilyn de Chantal; Thierry Charron; Robert Amyot; Erick Schampaert; Jean G. Diodati


Archive | 2008

Coronary Intervention Microvascular Obstruction and the No-Reflow Phenomenon After Percutaneous

Ronen Jaffe; Thierry Charron; Geoffrey Puley; Alexander Dick


Archive | 2007

Fabry's Cardiomyopathy: Diagnosis, Pathophysiology and the Role of Enzyme Replacement Therapy

Y. Oudit; Robert M. Iw; A Nochko; G Ordon Moe; Beth L. Abramson; Luigi Casella; Thierry Charron; Asim N. Cheema; Robert J. Chisholm; Chi-Ming Chow; Paul Dorian; David Fitchett; Michael R. Freeman; Shaun Goodman; Anthony F. Graham; Robert J. Howard; Stuart Hutchison; Victoria Korley; Michael Kutryk; Anatoly Langer; Howard Leong-Poi; Iqwal Mangat; Gordon W. Moe; Juan C. Monge; Thomas G. Parker; Arnold Pinter; Trevor I. Robinson; Duncan J. Stewart; Bradley H. Strauss

Collaboration


Dive into the Thierry Charron's collaboration.

Top Co-Authors

Avatar

Bradley H. Strauss

Sunnybrook Health Sciences Centre

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Guy Rousseau

Université de Montréal

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Luigi Casella

Sunnybrook Health Sciences Centre

View shared research outputs
Top Co-Authors

Avatar

Paul Dorian

Sunnybrook Health Sciences Centre

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge